FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2331255506> ?p ?o ?g. }

• W2331255506 endingPage "A55" @default.
• W2331255506 startingPage "A55" @default.
• W2331255506 abstract "Abstract Background: Activation of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor receptor (MET) pathway promotes tumor growth, invasion and dissemination. Emibetuzumab is a humanized IgG4 monoclonal antibody that binds to and inhibits ligand-dependent and ligand-independent activation of MET. In the first-in-human dose escalation study NCT0128756, emibetuzumab demonstrated favorable tolerability when administered up to 2000mg Q2W IV in unselected patients. The study was expanded to evaluate emibetuzumab in expansion cohorts for patients with tumors positive for MET expression. Methods: Patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC) with bone metastasis, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC) received 2000 mg emibetuzumab Q2W IV on a 28-day cycle. RCC, NSCLC, and HCC patients were required to have measurable disease as defined by RECIST v1.1 and have MET positive tumors (≥50% of cells to be ≥2+ for MET expression) as determined by a MET IHC assay (Ventana). The objectives were to evaluate the safety and activity of emibetuzumab in patients with MET positive tumors. Additional objectives included pharmacokinetics (PK) and pharmacodynamics (PD). Results: A total of 62 patients received emibetuzumab across the 4 cohorts: CRPC n = 15, RCC n = 19, NSCLC n = 19,and HCC n = 9, with a median of prior systemic oncology therapies of 6, 3, 5, and 3, respectively. Common possibly related treatment-emergent adverse events included fatigue (29% all grades, 3% Gr3/4), nausea (13% all grades, no Gr3/4), edema of limbs (8% all grades, 2% Gr3/4), and anorexia (8%, no Gr3/4) and were similar among cohorts. No evidence of clinical activity was observed in CRPC patients. For RCC, NSCLC, and HCC patients with MET positive tumors, an overall disease control rate (DCR = partial response [PR] + stable disease [SD]) of 32% (15/47) was observed. In the individual cohorts, DCR was 26% (5/19) in RCC, 26% (5/19) in NSCLC, and 56% (5/9) in HCC. The median duration of disease stabilization in the 3 cohorts was: 4.2 months (range 1.6-24.6) in RCC, 3.9 months (range 2.5-6.4) in NSCLC, and 3.7 months (range 1.2-6.6) in HCC. One PR was observed in an HCC patient with MET amplification. After a single dose of 2000 mg emibetuzumab, PK parameters were similar among these cohorts and also comparable to patients treated at this dose during dose escalation. Conclusions: In cohorts enriched for tumor MET expression, limited single-agent activity of emibetuzumab was observed indicating that MET positivity by IHC (Ventana assay) at the cut-point employed here might not be a sufficient predictive biomarker to select patients receiving benefit from emibetuzumab monotherapy for the tumor types studied. Further evaluation of biomarkers/assays to identify patients who may benefit from treatment with emibetuzumab may be warranted. Citation Format: Michaela S. Banck, Rashmi Chugh, Ronald B. Natale, Alain Algazi, Bradley C. Carthon, Lee S. Rosen, Michael E. Menefee, Andrew Xiuxuan Zhu, Takami Sato, Brian Moser, P. Kellie Turner, Jay Tuttle, Xuejing Aimee Wang, Volker Wacheck, Frederick E. Millard. Phase 1 results of emibetuzumab (LY2875358), a bivalent MET antibody, in patients with advanced castration-resistant prostate cancer, and MET positive renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A55." @default.
• W2331255506 created "2016-06-24" @default.
• W2331255506 creator A5009244604 @default.
• W2331255506 creator A5013629946 @default.
• W2331255506 creator A5016367638 @default.
• W2331255506 creator A5026290458 @default.
• W2331255506 creator A5035665916 @default.
• W2331255506 creator A5037041032 @default.
• W2331255506 creator A5037497042 @default.
• W2331255506 creator A5052459863 @default.
• W2331255506 creator A5053828591 @default.
• W2331255506 creator A5063855371 @default.
• W2331255506 creator A5066423217 @default.
• W2331255506 creator A5072582710 @default.
• W2331255506 creator A5084295219 @default.
• W2331255506 creator A5084569103 @default.
• W2331255506 creator A5088566246 @default.
• W2331255506 date "2015-12-01" @default.
• W2331255506 modified "2023-09-27" @default.
• W2331255506 title "Abstract A55: Phase 1 results of emibetuzumab (LY2875358), a bivalent MET antibody, in patients with advanced castration-resistant prostate cancer, and MET positive renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma" @default.
• W2331255506 doi "https://doi.org/10.1158/1535-7163.targ-15-a55" @default.
• W2331255506 hasPublicationYear "2015" @default.
• W2331255506 type Work @default.
• W2331255506 sameAs 2331255506 @default.
• W2331255506 citedByCount "7" @default.
• W2331255506 countsByYear W23312555062017 @default.
• W2331255506 countsByYear W23312555062018 @default.
• W2331255506 countsByYear W23312555062019 @default.
• W2331255506 countsByYear W23312555062021 @default.
• W2331255506 countsByYear W23312555062022 @default.
• W2331255506 crossrefType "journal-article" @default.
• W2331255506 hasAuthorship W2331255506A5009244604 @default.
• W2331255506 hasAuthorship W2331255506A5013629946 @default.
• W2331255506 hasAuthorship W2331255506A5016367638 @default.
• W2331255506 hasAuthorship W2331255506A5026290458 @default.
• W2331255506 hasAuthorship W2331255506A5035665916 @default.
• W2331255506 hasAuthorship W2331255506A5037041032 @default.
• W2331255506 hasAuthorship W2331255506A5037497042 @default.
• W2331255506 hasAuthorship W2331255506A5052459863 @default.
• W2331255506 hasAuthorship W2331255506A5053828591 @default.
• W2331255506 hasAuthorship W2331255506A5063855371 @default.
• W2331255506 hasAuthorship W2331255506A5066423217 @default.
• W2331255506 hasAuthorship W2331255506A5072582710 @default.
• W2331255506 hasAuthorship W2331255506A5084295219 @default.
• W2331255506 hasAuthorship W2331255506A5084569103 @default.
• W2331255506 hasAuthorship W2331255506A5088566246 @default.
• W2331255506 hasConcept C121608353 @default.
• W2331255506 hasConcept C126322002 @default.
• W2331255506 hasConcept C143998085 @default.
• W2331255506 hasConcept C197934379 @default.
• W2331255506 hasConcept C2776256026 @default.
• W2331255506 hasConcept C2776694085 @default.
• W2331255506 hasConcept C2777472916 @default.
• W2331255506 hasConcept C2777546739 @default.
• W2331255506 hasConcept C2778375690 @default.
• W2331255506 hasConcept C2779013556 @default.
• W2331255506 hasConcept C2779984678 @default.
• W2331255506 hasConcept C2780192828 @default.
• W2331255506 hasConcept C31760486 @default.
• W2331255506 hasConcept C71924100 @default.
• W2331255506 hasConceptScore W2331255506C121608353 @default.
• W2331255506 hasConceptScore W2331255506C126322002 @default.
• W2331255506 hasConceptScore W2331255506C143998085 @default.
• W2331255506 hasConceptScore W2331255506C197934379 @default.
• W2331255506 hasConceptScore W2331255506C2776256026 @default.
• W2331255506 hasConceptScore W2331255506C2776694085 @default.
• W2331255506 hasConceptScore W2331255506C2777472916 @default.
• W2331255506 hasConceptScore W2331255506C2777546739 @default.
• W2331255506 hasConceptScore W2331255506C2778375690 @default.
• W2331255506 hasConceptScore W2331255506C2779013556 @default.
• W2331255506 hasConceptScore W2331255506C2779984678 @default.
• W2331255506 hasConceptScore W2331255506C2780192828 @default.
• W2331255506 hasConceptScore W2331255506C31760486 @default.
• W2331255506 hasConceptScore W2331255506C71924100 @default.
• W2331255506 hasIssue "12_Supplement_2" @default.
• W2331255506 hasLocation W23312555061 @default.
• W2331255506 hasOpenAccess W2331255506 @default.
• W2331255506 hasPrimaryLocation W23312555061 @default.
• W2331255506 hasRelatedWork W1722662989 @default.
• W2331255506 hasRelatedWork W2050285695 @default.
• W2331255506 hasRelatedWork W2129608087 @default.
• W2331255506 hasRelatedWork W2145046367 @default.
• W2331255506 hasRelatedWork W2212921542 @default.
• W2331255506 hasRelatedWork W2354998662 @default.
• W2331255506 hasRelatedWork W2539641070 @default.
• W2331255506 hasRelatedWork W3166323315 @default.
• W2331255506 hasRelatedWork W4310754081 @default.
• W2331255506 hasRelatedWork W53594158 @default.
• W2331255506 hasVolume "14" @default.
• W2331255506 isParatext "false" @default.
• W2331255506 isRetracted "false" @default.
• W2331255506 magId "2331255506" @default.
• W2331255506 workType "article" @default.